242 related articles for article (PubMed ID: 35764393)
1. Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients.
Attias P; Azzaoui I; El Karoui K; de La Selle A; Sokal A; Chappert P; Grimbert P; Fernandez I; Bouvier M; Samson C; Dahmane D; Rieu P; Nizard P; Fourati S; Sakhi H; Mahévas M;
Clin J Am Soc Nephrol; 2022 Jul; 17(7):1008-1016. PubMed ID: 35764393
[TBL] [Abstract][Full Text] [Related]
2. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
4. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.
Goel RR; Apostolidis SA; Painter MM; Mathew D; Pattekar A; Kuthuru O; Gouma S; Hicks P; Meng W; Rosenfeld AM; Dysinger S; Lundgreen KA; Kuri-Cervantes L; Adamski S; Hicks A; Korte S; Oldridge DA; Baxter AE; Giles JR; Weirick ME; McAllister CM; Dougherty J; Long S; D'Andrea K; Hamilton JT; Betts MR; Luning Prak ET; Bates P; Hensley SE; Greenplate AR; Wherry EJ
Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33858945
[TBL] [Abstract][Full Text] [Related]
5. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
6. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
7. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
8. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies.
Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A
Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of Humoral and Cellular Responses in Renal Transplant Recipients Receiving 3 Doses of SARS-CoV-2 mRNA Vaccine.
Arias-Cabrales C; Folgueiras M; Faura A; Eguia J; Padilla E; Hurtado S; Ribera L; Echeverria-Esnal D; Pérez-Sáez MJ; Redondo-Pachón D; Burballa C; Buxeda A; Llinàs-Mallol L; Cao H; Barbosa F; Rovira X; Cima F; Pascual J; Crespo M
Transplantation; 2023 Feb; 107(2):457-465. PubMed ID: 36584381
[TBL] [Abstract][Full Text] [Related]
10. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis.
Espi M; Charmetant X; Barba T; Mathieu C; Pelletier C; Koppe L; Chalencon E; Kalbacher E; Mathias V; Ovize A; Cart-Tanneur E; Bouz C; Pellegrina L; Morelon E; Juillard L; Fouque D; Couchoud C; Thaunat O;
Kidney Int; 2022 Feb; 101(2):390-402. PubMed ID: 34856313
[TBL] [Abstract][Full Text] [Related]
11. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
Front Immunol; 2021; 12():690698. PubMed ID: 34276681
[TBL] [Abstract][Full Text] [Related]
13. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
[TBL] [Abstract][Full Text] [Related]
14. Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose.
Mangia A; Serra N; Cocomazzi G; Giambra V; Antinucci S; Maiorana A; Giuliani F; Montomoli E; Cantaloni P; Manenti A; Piazzolla V
Front Public Health; 2022; 10():847384. PubMed ID: 35433614
[TBL] [Abstract][Full Text] [Related]
15. A Single Dose of BNT162b2 Messenger RNA Vaccine Induces Airway Immunity in Severe Acute Respiratory Syndrome Coronavirus 2 Naive and Recovered Coronavirus Disease 2019 Subjects.
Martinuzzi E; Benzaquen J; Guerin O; Leroy S; Simon T; Ilie M; Hofman V; Allegra M; Tanga V; Michel E; Boutros J; Maniel C; Sicard A; Glaichenhaus N; Czerkinsky C; Blancou P; Hofman P; Marquette CH
Clin Infect Dis; 2022 Dec; 75(12):2053-2059. PubMed ID: 35579991
[TBL] [Abstract][Full Text] [Related]
16. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients.
Becker M; Cossmann A; Lürken K; Junker D; Gruber J; Juengling J; Ramos GM; Beigel A; Wrenger E; Lonnemann G; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Strengert M; Dulovic A; Behrens GMN
Front Immunol; 2022; 13():1004045. PubMed ID: 36275672
[TBL] [Abstract][Full Text] [Related]
19. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
[TBL] [Abstract][Full Text] [Related]
20. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
